{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:31:39Z","timestamp":1791113499167,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T00:00:00Z","timestamp":1250121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir\/ritonavir monotherapy to triple combination therapy with zidovudine\/lamivudine and lopinavir\/ritonavir in antiretroviral\u2010na\u00efve patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 136 antiretroviral\u2010na\u00efve patients, with a CD4 cell count above 100\u2003cells\/\u03bcL and a plasma HIV RNA below 100\u2003000 HIV\u20101 RNA copies\/mL, were randomized and dosed with either lopinavir\/ritonavir monotherapy (<jats:italic>n<\/jats:italic>=83) or lopinavir\/ritonavir+zidovudine\/lamivudine (<jats:italic>n<\/jats:italic>=53). We focus here on patients in the lopinavir\/ritonavir monotherapy arm followed to week 96. The intent\u2010to\u2010treat (ITT) analysis initially involved all patients randomized to lopinavir\/ritonavir monotherapy (<jats:italic>n<\/jats:italic>=83), and then focused on patients who had an HIV RNA &lt;50\u2003copies\/mL at week 48 (<jats:italic>n<\/jats:italic>=56).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 96, 39 of 83 patients (47%) had HIV RNA &lt;50\u2003copies\/mL, five of 83 had HIV RNA between 50 and 400\u2003copies\/mL, and three of 83 had HIV RNA &gt;400\u2003copies\/mL. Focusing on the 56 patients with an HIV RNA &lt;50\u2003copies\/mL at week 48, 38 of 56 patients (68%) had a sustained HIV RNA &lt;50\u2003copies\/mL to week 96. To week 96, a total of 28 patients (34%) had discontinued the study treatment. In addition, the allocated treatment was changed for seven patients. PI\u2010associated resistance mutations were evident in five of 83 patients in the monotherapy arm from baseline to week 96.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By ITT analysis, 39 of the 83 patients initially randomized to lopinavir\/ritonavir monotherapy had HIV RNA &lt;50\u2003copies\/mL at week 96. The occurrence in some patients of low\u2010level viraemia (50\u2013500\u2003copies\/mL) may increase the risk of drug resistance. First\u2010line lopinavir\/ritonavir monotherapy cannot be systematically recommended.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00752.x","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T08:54:08Z","timestamp":1250153648000},"page":"137-142","source":"Crossref","is-referenced-by-count":32,"title":["Long\u2010term (96\u2010week) follow\u2010up of antiretroviral\u2010na\u00efve HIV\u2010infected patients treated with first\u2010line lopinavir\/ritonavir monotherapy in the MONARK trial<sup>*<\/sup>"],"prefix":"10.1111","volume":"11","author":[{"given":"J","family":"Ghosn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Flandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Cohen\u2010Codar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u2010M","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2010L","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dellamonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"NgoVan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u2010F","family":"Delfraissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the MONARK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,4]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"555","article-title":"Antiretroviral treatment of adult HIV infection","volume":"300","author":"Hammer SM","year":"2008","journal-title":"2008 recommendations of the International AIDS Society-USA Panel"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199816000-00011"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl191"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350300800304"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20140"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm364"},{"key":"e_1_2_6_9_2","first-page":"280","article-title":"Lopinavir\/ritonavir as single\u2010drug therapy for maintenance of HIV\u20101 viral suppression","volume":"40","author":"Arribas JR","year":"2005","journal-title":"48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)"},{"key":"e_1_2_6_10_2","unstructured":"NunesEP OliveiraMS AlmeidaMMet al. 48\u2013week efficacy and safety results of simplification to single agent lopinavir\/ritonavir (LPV\/r) regimen in patients suppressed below 80 copies\/mL on HAART\u2014the KalMo Study.16th International Conference on AIDS. Toronto ON August 2006 [Abstract TUAB0102]."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f4243b"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/589622"},{"key":"e_1_2_6_13_2","unstructured":"GatheJC MayberryC MiguelB NemecekJ YehR.Long\u2010term follow\u2010up of IMANI\u20131: pilot study of the safety and efficacy of lopinavir\/ritonavir (LPV\/r) as single agent therapy (SAT) in HIV\u20101 antiretroviral (ARV)\u2010na\u00efve patients.8th Annual International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2006 [Abstract P5]."},{"key":"e_1_2_6_14_2","unstructured":"GatheJC YehRF MayberryCet al. Single\u2010agent therapy with lopinavir\/ritonavir suppresses plasma HIV\u20101 viral replication in HIV\u20101 na\u00efve subjects: IMANI\u20102 48\u2010week results.4th IAS Conference. Sydney Australia July 2007 [Abstract WePeB034]."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f3f16d"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01643-08"},{"key":"e_1_2_6_17_2","first-page":"4","article-title":"Ritonavir\u2010boosted protease inhibitor monotherapy for the treatment of HIV\u20101 infection","volume":"10","author":"Sahali S","year":"2008","journal-title":"AIDS Rev"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00024"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409240-00016"},{"key":"e_1_2_6_20_2","unstructured":"GutmannC OpravilM FuxCet al. Unexpectedly high failure rate in LPV\/r monotherapy arm involving CNS and associated with low nadir CD4 count in the MOST Study.16th Conference on Retroviruses and Opportunistic Infections. Montreal QC February 2009 [Abstract 578]."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/523002"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.aids.0000171409.38490.48","article-title":"Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV","volume":"19","author":"Capparelli EV","journal-title":"AIDS"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410025320"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn098"},{"key":"e_1_2_6_25_2","first-page":"1062","article-title":"Potential risks and benefits of HIV treatment simplification","volume":"45","author":"Schackman BR","year":"2007","journal-title":"a simulation model of a proposed clinical trial"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00752.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00752.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:11:11Z","timestamp":1698657071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00752.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00752.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00752.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,4]]}}}